Gang Liu | Medicine and Health Sciences | Best Researcher Award

Published on by Cognitive Scientist Awards

Prof. Gang Liu | Medicine and Health Sciences| Best Researcher Award

The Affiliated Hospital of Guizhou Medical University | China

Gang Liu, M.D., is a highly regarded Professor and Chief Physician of Orthopaedics at the Department of Emergency Orthopedics, The Affiliated Hospital of Guizhou Medical University. Serving also as a Master’s Supervisor, Dr. Liu has made substantial contributions to orthopaedic trauma care, with a clinical and academic career rooted in improving outcomes for patients with complex fractures and injuries. Known for his precision in surgical techniques and commitment to academic mentoring, he leads innovative research in trauma surgery and biomechanics. His leadership in the department reflects his dedication to clinical excellence, education, and advancing orthopaedic science. As an influential voice in orthopaedic medicine in China, Dr. Liu combines decades of hands-on experience with a forward-looking approach to research and treatment, helping shape the next generation of specialists in trauma care. His work bridges the gap between clinical application and academic research, fostering advancements in evidence-based orthopaedic medicine.

Profile

ORCID

Education

While specific educational details about Dr. Gang Liu are not publicly listed, his current academic and professional status indicates extensive medical training, including the attainment of a Doctor of Medicine (M.D.) degree, likely followed by specialized residency and fellowship programs in orthopaedic surgery. As a Professor and Chief Physician, he has undoubtedly completed postgraduate and professional training in trauma and emergency orthopaedics, biomechanics, and surgical innovation. His role as a Master’s Supervisor suggests strong academic foundations and consistent engagement with scholarly research. Dr. Liu is affiliated with Guizhou Medical University, where he likely received or has contributed significantly to medical education. His educational trajectory exemplifies the rigorous academic and clinical preparation typical of senior physician-scientists in China’s leading medical institutions. His expertise reflects years of advanced learning in both clinical practice and orthopaedic science, enabling him to train the next generation of surgeons and researchers with a firm grounding in trauma and biomechanics.

Experience

Dr. Gang Liu currently serves at the Affiliated Hospital of Guizhou Medical University in Guiyang, China, where he is a Professor, Chief Physician in Orthopaedics, and a Master’s Supervisor. With decades of clinical and teaching experience, he plays a pivotal role in emergency orthopaedics, specializing in trauma management and fracture treatment. His leadership in the Department of Emergency Orthopedics involves not only patient care but also surgical innovation and departmental development. Dr. Liu has extensive experience in applying biomechanics to orthopaedic practice, aligning clinical strategies with research-based methodologies. His commitment to teaching and mentoring graduate students positions him as a key academic figure within the university. He integrates research, clinical service, and academic mentorship, demonstrating a rare balance of practical and theoretical knowledge in orthopaedics. His experience reflects the depth of his involvement in complex surgical procedures, clinical trials, and strategic planning for orthopaedic care in academic hospital settings.

Awards and Honors

Although detailed information on Dr. Gang Liu’s specific awards and honors is not publicly disclosed, his distinguished titles—Professor, Chief Physician, and Master’s Supervisor—indicate recognition for excellence in clinical practice, education, and research. Such positions in China’s medical hierarchy are awarded based on years of exceptional service, academic contributions, and leadership in healthcare delivery. It is likely that Dr. Liu has received institutional commendations and possibly regional or national recognition for his work in trauma and fracture care. His role in mentoring postgraduates suggests academic honors or commendations for teaching and research guidance. His contributions to biomechanics research and emergency orthopaedics may have earned him research grants or hospital-level awards for innovation or service excellence. As a senior figure at the Affiliated Hospital of Guizhou Medical University, he exemplifies the attributes of a respected physician-scientist whose reputation is built on both clinical outcomes and contributions to the academic and research mission of the institution.

Research Focus

Dr. Gang Liu’s research focuses on trauma, fracture management, and biomechanics in orthopaedic medicine. His work aims to improve understanding of the mechanical and biological responses of bone and soft tissue to injury, optimizing both surgical techniques and recovery outcomes. He explores how trauma impacts musculoskeletal function and how biomechanics can inform fracture fixation and healing strategies. At the Department of Emergency Orthopedics, Dr. Liu integrates research into clinical practice, conducting translational studies that advance evidence-based protocols in trauma care. His investigations likely include experimental and clinical trials, examining both traditional and modern surgical interventions. Emphasizing interdisciplinary collaboration, his research contributes to innovations in implant design, bone regeneration, and trauma surgery protocols. As a Master’s Supervisor, he mentors students on research methodologies, encouraging rigorous scientific exploration in orthopaedics. Dr. Liu’s research strengthens the link between clinical need and scientific discovery in the rapidly evolving field of emergency orthopaedic care.

Conclusion

Dr. Gang Liu stands as a dedicated leader in orthopaedic trauma care, combining clinical expertise, academic mentorship, and biomechanical research to improve patient outcomes and train future surgeons.

Muhammad Zia | Pharmacology | Best Researcher Award

Published on by Cognitive Scientist Awards

Dr. Muhammad Zia | Pharmacology | Best Researcher Award

College of staten island | United States

Dr. Muhammad K. Zia is a medical professional and educator specializing in biological and medical sciences, currently serving as a Doctoral Lecturer in the Department of Biology at the College of Staten Island/CUNY. With an M.B.B.S. from Jinnah Sindh Medical University, Dr. Zia brings over two decades of diverse experience spanning clinical practice, higher education, and scientific research. He has contributed significantly to undergraduate science education through positions at Kean University, Fairleigh Dickinson University, and other academic institutions. His clinical background includes roles in pathology and diabetology in both the U.S. and Pakistan. Notably, he was awarded the PSC-CUNY research grant to study the effects of angiotensin receptor blockers on diabetic nephropathy. A dedicated mentor and presenter, Dr. Zia has supervised multiple student research posters and actively contributes to academic development at CSI. His interdisciplinary expertise uniquely bridges clinical knowledge with life science education and research.

Profile

ORCID

Education

Dr. Muhammad K. Zia earned his medical degree (M.B.B.S.) from Jinnah Sindh Medical University in Karachi, Pakistan. His training equipped him with a solid foundation in clinical medicine, including internal medicine, diagnostics, pathology, and patient care. Following graduation, he pursued additional clinical training and gained certification to practice medicine in Pakistan. Over time, he transitioned into academic medicine, combining his clinical expertise with pedagogy in biological sciences. He has complemented his education with ongoing professional development and has contributed to academic settings through student mentorship, course delivery, and research guidance. His deep understanding of clinical biology, pathology, and pharmacological interventions forms the basis of his teaching philosophy. While he holds no formal advanced academic degrees beyond his medical license, Dr. Zia has consistently demonstrated a commitment to educational excellence and medical scholarship, as evidenced by his active teaching roles and scholarly contributions in academic institutions in both the U.S. and abroad.

Experience

Dr. Zia’s professional journey reflects a balanced blend of academic instruction and clinical medicine. He has served as a Doctoral Lecturer at the College of Staten Island, following 12 years as an adjunct and substitute instructor. His teaching experience also spans Kean University, Union County College, Stevens Institute of Technology, and Wagner College, where he taught various biology and medical science courses. In the clinical domain, Dr. Zia has worked as a Medical Assistant in New Jersey, a Pathology Assistant at QDx Pathology Services, and held roles such as Associate Diabetologist and Resident Medical Officer at Baqai Medical University. Earlier in his career, he served as a Clinical Assistant at Imam Clinic in Karachi. His clinical responsibilities included diagnostics, treatment planning, minor procedures, and patient education. This extensive experience across multiple institutions showcases his ability to deliver science education enriched by real-world medical practice.

Awards and Honors

Dr. Muhammad K. Zia has been recognized for his commitment to academic research and mentorship through the PSC-CUNY Cycle 54 Research Grant. The award supported his study on the effects of Angiotensin Receptor Blockers in diabetic nephropathy, showcasing his initiative in clinical and retrospective research. His efforts to promote scientific inquiry among undergraduates were further highlighted through his supervision of multiple poster presentations at the CSI Undergraduate Conference on Research, Scholarship, and Arts. These included literature reviews on SGLT2 inhibitors, Parkinson’s disease interventions, and cardiovascular risks linked to supraventricular tachycardia. Dr. Zia has also presented workshops such as “How to Write a Reference Letter to Support Pre-Med Students,” contributing to the academic development of aspiring physicians. While he may not yet have amassed a wide array of traditional academic honors, his consistent involvement in student mentorship, curriculum enrichment, and funded research speaks volumes about his dedication and impact.

Research Focus

Dr. Zia’s research interests center on the intersection of clinical medicine and chronic disease management. His primary focus includes diabetic complications, particularly diabetic nephropathy and the therapeutic role of angiotensin receptor blockers. He is also interested in cardiovascular pharmacology and endocrinology, as demonstrated by his guidance of student research on SGLT2 inhibitors and their cardioprotective effects. His approach often involves retrospective chart reviews and critical literature analysis using credible medical databases like PubMed and the European Journal of Medicine. He further engages in collaborative educational research and academic mentoring, particularly within undergraduate settings. Dr. Zia’s supervised projects span diverse clinical areas, such as Parkinson’s disease interventions and arrhythmia outcomes, reflecting his broad scientific curiosity and integrative knowledge of pathophysiology. Through these initiatives, he fosters critical thinking and evidence-based research skills among students, contributing to a stronger foundation in translational medicine and interdisciplinary health sciences education.

Publications

Title: Comparative Evaluation of ARB Monotherapy and SGLT2/ACE Inhibitor Combination Therapy in the Renal Function of Diabetes Mellitus Patients: A Retrospective, Longitudinal Cohort Study
Year: 2025

Conclusion

Dr. Muhammad K. Zia’s multidimensional career—rooted in clinical medicine and expanded through academic instruction and student mentorship—demonstrates a sustained commitment to bridging medical science with impactful education and applied research.

Yingna Le | Research on the Mechanism of Action of Active Ingredients in Traditional Chinese Medicine | Best Researcher Award

Published on by Cognitive Scientist Awards

Dr. Yingna Le | Research on the Mechanism of Action of Active Ingredients in Traditional Chinese Medicine | Best Researcher Award

PhD Candidate| Nanchang Medical College, china

Dr. Yingna Le is a Lecturer in Pharmacy at Nanchang Medical College’s School of Pharmacy, where she specializes in pharmacognosy and the authentication of Chinese medicinal materials. With a strong foundation in Chinese Materia Medica from Yunnan and Jiangxi Universities of Traditional Chinese Medicine, she combines traditional knowledge with modern scientific research. Dr. Le actively investigates the molecular mechanisms behind active ingredients in Traditional Chinese Medicine (TCM), contributing to national and provincial research projects. Her work includes the study of hawthorn leaf flavonoids and kidney stone treatments through the lens of network pharmacology and gut-liver axis analysis. She has published in core Chinese and international journals, developed flipped classroom models, and innovated WeChat-based educational tools. A member of several professional societies, she is committed to advancing TCM education and research. Her interdisciplinary approach integrates experimental design, pharmacognosy, and data analysis to enrich teaching and contribute to the scientific community.

Profile

🎓 Education

Dr. Yingna Le holds both Bachelor’s and Master’s degrees in Chinese Materia Medica. She earned her B.S. from Yunnan University of Traditional Chinese Medicine in 2007, where she developed a strong understanding of traditional pharmacognosy and the foundational principles of Chinese medicine. She then pursued her M.S. from Jiangxi University of Traditional Chinese Medicine (2008–2011), deepening her expertise in medicinal material authentication and TCM pharmacology. Her postgraduate studies provided her with skills in microscopic identification, phytochemical analysis, and TCM theory, setting the stage for her research and teaching career. This rigorous academic background enabled her to bridge the gap between traditional practices and contemporary scientific methods. Her educational journey laid the groundwork for her future roles in academia and research, where she continues to explore the integration of modern pharmacological techniques with ancient herbal wisdom. Dr. Le’s academic path demonstrates her dedication to excellence and innovation in the field of TCM.

🧪 Experience

Dr. Yingna Le currently serves as a Lecturer in the School of Pharmacy at Nanchang Medical College (2021–present), where she teaches Pharmacognosy and the Authentication of Chinese Medicinal Materials. Prior to this, she was a Teaching Assistant at the Jiangxi University of TCM Science and Technology College (2018–2021), where she began integrating innovative teaching strategies into traditional Chinese medicine education. Her academic career is marked by a dedication to improving teaching quality through flipped classrooms and the application of digital platforms like WeChat for student engagement and evaluation. In addition to teaching, Dr. Le has played pivotal roles in research, particularly as Principal Investigator and Co-Investigator on national and provincial research grants. She has completed five interdisciplinary projects between 2020 and 2022 and actively contributes to academic publications. Her blend of instructional innovation and research acumen makes her a respected figure in both educational and scientific circles in TCM.

🏅 Awards and Honors

Dr. Yingna Le has earned recognition through competitive research funding and influential academic appointments. She is the Principal Investigator of a Jiangxi Provincial Education Department grant for studying Lygodium japonicum’s mechanisms against kidney stones, and a Co-Investigator on a prestigious National Natural Science Foundation of China (NSFC) grant examining hawthorn leaf flavonoids in cardiovascular treatment. While specific award titles are not listed, her success in securing these high-level grants reflects her scientific credibility and innovation. Additionally, her involvement in five interdisciplinary education reform and material science projects (2020–2022) with substantial budgets highlights her leadership and collaborative spirit. Dr. Le also holds committee roles in key professional societies, including the TCM Processing Committee of the Jiangxi Pharmaceutical Association and the Digital Healthcare & Simulation Medicine Society of Jiangxi Province. These roles further affirm her status as a trusted contributor to the advancement of pharmacy education and research in Traditional Chinese Medicine.

🔬 Research Focus

Dr. Yingna Le’s research centers on uncovering the mechanisms of action of active ingredients in Traditional Chinese Medicine using modern pharmacological approaches. Her work focuses on compounds such as hawthorn leaf flavonoids and their effects on cardiovascular health, particularly unstable plaques, through the LXR-α mediated modulation of iron-lipid metabolism in the gut-liver axis. She also investigates the therapeutic potential of Lygodium japonicum in kidney stone treatment via network pharmacology. Dr. Le employs a range of methodologies including phytochemical analysis, molecular mechanism studies, and pharmacognostic techniques. Her research approach integrates traditional herbal knowledge with systems biology to bridge classical TCM theory with modern biomedical science. She has a strong interest in interdisciplinary collaboration and has led or contributed to numerous research projects across pharmacology, education reform, and material science. Her contributions aim to validate and modernize the application of traditional remedies in contemporary clinical settings, making her work both culturally relevant and scientifically impactful.

✅ Conclusion

Dr. Yingna Le blends traditional Chinese medical expertise with modern research to advance pharmacognosy and medicinal authentication. Through dedicated teaching, impactful research, and innovative education methods, she contributes significantly to TCM modernization.

Publications

Hongjun JIN | Nuclear Medicine Molecular Imaging | Interdisciplinary Innovation Prize

Published on by Cognitive Scientist Awards

Prof Dr.  Hongjun JIN | Nuclear Medicine Molecular Imaging | Interdisciplinary Innovation Prize

: Sun Yat-sen University Fifth Affiliated Hospital, china

Profile

Education

Dr. Hongjun Jin is a Principal Investigator in Nuclear Medicine and a Doctoral Supervisor of Molecular Medicine at Sun Yat-sen University. He earned his PhD in Biochemistry from Texas A&M University in 2007, following a BS in Radiochemistry from Lanzhou University in 1994 and a BMed in Chinese Medicine from Beijing University of Chinese Medicine in 1997. He completed his postdoctoral training at PNNL from 2008 to 2012 and served as a radiology instructor at Washington University in St. Louis from 2012 to 2017. Since 2017, he has led the PET and radiochemical laboratory at his institute, having been recruited through Sun Yat-sen University’s “Hundred Talents Program.”

Research and Innovations:

1) General Research Fund for National Sciences Foundation of China (NSFC), 82372004,
“F-18 labelled PET probe targeting P2X7 receptor for Evaluation of Treatment for AD”
01/01/2024-12/31/2027￥480,000,
2) Key R&D project, 0007/2022/AKP, Macao S&T Fund (FDCT),“R&D of an Integrated
Molecular probe for Targeted TNFR2 New Tumor Diagnosis and
Treatment”,01/01/2024-12/31/2027,￥2,400,000 (out of ￥120,000,000)
3) Guangdong Provincial Enterprise Joint Fund, 2021A1515220004, Guangdong Province
“PET/MRI Neuromolecular Imaging Quantitative Study of New Drug Targeting Sigma1

Research Project

  • 1) Outstanding Foreign Young Scientist Talent Program, RFIS, 82150610508 NSF-CN，
    “ Establishment and drug evaluation of acetylcholinergic and dopaminergic
    neuromolecular probes (18F VAT and 18F-DTBZ) PET brain imaging quantitative
    system for Parkinson’s disease” 2022/01-2022/12，￥400,000
  • General Research Fund for NSFC, 81871382, “F-18 labelled PET probe targeting P2X7
    receptor for early detection of AD”01/01/2019-12/31/2022￥570,000
  • SYSU “Hundred Talent “Starting Fund (Period I)” SYSU-FA10/01/2017-09/30/2022
    ￥2,500,000
  • National Key R&D Program for Precision Medicine, 2018YFC0910601 Real-time, highdimensional, multi-modality imaging co-registration and theronoastic strategies for
    oesophageal squamous-cell carcinomas10/01/2018-12/31/2020￥1,272,500 (out of
    ￥19,230,000)
  • Sun Yat-sen University Military Industry Cultivation Project, 89000-18843403 SYSU
    “Key Technologies of Molecular Imaging of Immune Dysfunction in Microgravity
    Environment”, 2019/08-2021/12￥1,890,00
  • Researchers Initiate Clinical Research Project (IIT) Award, SYSU-FAH”A single-center,
    open, prospective assessment of the diagnostic significance of 18F-FDG PET/CT
    dynamic imaging and gene sequencing in detecting metastatic lesions of non-small cell
    lung cancer”,2020/10-2021/09￥50,000
  • COVID-19 infection prevention and control emergency S&T, ZH22036302200036PWC,
    Zhuhai City”Specific Targeting S- protein of SARS-CoV-2 PET molecular imaging
    probe”2020/08-2021/09,￥70,000

Citation Index:

Google Scholar Citations: 8684 (total) 7943 (since 2020)
h-index 26(total) 20 (since 2020)
i10-index 52(total) 39(since 2020)

Publications

Rohit Pal | Pharmaceutical Chemistry | Young Scientist Award

Published on by Cognitive Scientist Awards

Mr. Rohit Pal | Pharmaceutical Chemistry | Young Scientist Award

PhD Scholar at Acharya and BM Reddy College of Pharmacy, Bengaluru, India

Mr. Rohit Pal is a dedicated and emerging researcher in the field of pharmaceutical sciences, particularly focusing on drug discovery and development. Currently pursuing his Ph.D. at Acharya & BM Reddy College of Pharmacy in Bengaluru, he is engaged in innovative research on Pyrimidine derivatives as fourth-generation EGFR inhibitors to combat Non-Small Cell Lung Cancer (NSCLC). With a strong academic background, including an M.Pharmacy in Pharmaceutical Chemistry, Mr. Pal combines his expertise in chemical synthesis with cutting-edge computational techniques like molecular docking and structure-activity relationship (SAR) analysis. His work spans multiple research areas, including anticonvulsant activity, anti-inflammatory research, and the pharmacognostic standardization of endangered species like Passiflora vitifolia. Throughout his career, Mr. Pal has demonstrated a capacity for both in-silico drug design and experimental testing, balancing theoretical approaches with hands-on experimentation. His impressive publication record in respected journals further showcases his capability to contribute to the scientific community. As a promising young researcher, Mr. Pal’s ongoing work not only advances pharmaceutical sciences but also holds potential for meaningful clinical applications in cancer therapy and drug design.

Profile

Orcid

 

Education 🎓

Mr. Rohit Pal’s educational background demonstrates a consistent pursuit of excellence in the field of pharmaceutical sciences. He is currently enrolled in a Ph.D. program at Acharya & BM Reddy College of Pharmacy in Bengaluru, Karnataka, where his research is focused on the development of Pyrimidine derivatives as EGFR inhibitors to target Non-Small Cell Lung Cancer (NSCLC). Prior to his doctoral studies, Mr. Pal completed his M.Pharmacy in Pharmaceutical Chemistry from ISF College of Pharmacy in Moga, Punjab, achieving a notable CGPA of 9.07. His academic journey began with a B. Pharmacy from Dev Bhoomi Institute of Pharmacy and Research, Dehradun, where he gained a robust foundation in pharmaceutical sciences. Additionally, Mr. Pal holds a D. Pharmacy from SGGS College of Pharmacy, Chandigarh, further demonstrating his dedication to the field from the onset of his academic career. His varied educational experiences have shaped his interdisciplinary approach to pharmaceutical research, combining knowledge from chemistry, biology, and computational sciences. This solid academic foundation has propelled Mr. Pal to explore complex drug development challenges, particularly in cancer therapy, with a keen interest in molecular-level drug interactions.

Work Experience 💼

Mr. Rohit Pal’s professional experience reflects a promising trajectory in pharmaceutical research and drug discovery. As a Ph.D. scholar at Acharya & BM Reddy College of Pharmacy, he is deeply involved in researching Pyrimidine derivatives for EGFR inhibition in Non-Small Cell Lung Cancer (NSCLC). His research explores the design, synthesis, and evaluation of novel drug candidates, combining in-vitro testing with computational drug design. Through the use of molecular docking and structure-activity relationship (SAR) analysis, Mr. Pal aims to identify compounds with high therapeutic potential. Beyond his Ph.D. work, Mr. Pal has worked on various other research projects, including 1,2,4-triazine derivatives for anticonvulsant activity and the anti-inflammatory properties of Passiflora vitifolia, an endangered plant species. His work spans both synthetic chemistry and biological testing, allowing him to gain expertise in pharmacological assays and computational modeling. Mr. Pal’s professional experience also includes using sophisticated instruments such as HPLC, UV spectrophotometers, and Microwave Synthesizers, which complement his experimental work and ensure the reliability of his results. These experiences have positioned him well for future leadership roles in pharmaceutical research and drug developmen

Awards and Honors

Although still in the early stages of his academic career, Mr. Rohit Pal has already garnered significant recognition for his research efforts. His academic excellence is reflected in his M.Pharmacy CGPA of 9.07, placing him among the top students in his cohort. Mr. Pal’s research has been published in reputable journals such as the Journal of Biomolecular Structure and Dynamics and Chemical Physics Impact, demonstrating the impact and quality of his work. These publications are indicative of his ability to produce research that contributes to the scientific community. Despite being early in his career, his involvement in cutting-edge research on Pyrimidine derivatives and EGFR inhibitors has already gained attention within the academic and pharmaceutical fields. His dedication to molecular docking, drug design, and pharmacognostic studies positions him for further recognition. As Mr. Pal continues to contribute to innovative drug development solutions, he is likely to receive more prestigious awards and honors, reflecting the growing importance of his work in cancer research and pharmaceutical chemistry.

Research Interests

Mr. Rohit Pal’s research interests are centered around the intersection of pharmaceutical chemistry and drug discovery. His primary focus is on developing Pyrimidine derivatives as fourth-generation EGFR inhibitors aimed at Non-Small Cell Lung Cancer (NSCLC), a serious health concern with limited therapeutic options. By targeting the epidermal growth factor receptor (EGFR), his work could offer more effective treatment alternatives for cancer patients. In addition to cancer research, Mr. Pal has explored 1,2,4-triazine derivatives for evaluating anticonvulsant activity, contributing to neurological disorder treatments. He is also interested in anti-inflammatory research, with a particular focus on Passiflora vitifolia, an endangered plant species, aiming to standardize its pharmacognostic properties. His multidisciplinary approach extends to the application of computational drug design, where he utilizes molecular docking and molecular dynamics simulations to predict drug-receptor interactions. Mr. Pal is committed to advancing drug development by combining experimental chemistry with in-silico methodologies, offering innovative solutions for complex healthcare challenges. His work on drug repurposing, targeted therapies, and sustainable drug sourcing reflects his holistic approach to addressing both scientific and global health concerns.

Research Skills

Mr. Rohit Pal possesses a wide range of research skills essential for successful pharmaceutical research. His proficiency in chemical synthesis includes techniques such as recrystallization, sublimation, and flash chromatography, which he applies to purify and isolate new compounds for testing. In addition to these laboratory techniques, Mr. Pal is highly skilled in analytical methods, including HPLC and UV spectrophotometry, to assess the purity and chemical composition of compounds. He is also adept at utilizing computational tools for drug design, particularly AutoDock, Biovia Drug Discovery Studio, and Pymol, to perform molecular docking and molecular dynamics simulations. These tools allow him to predict the interactions between drug candidates and their targets, enhancing the efficiency of drug development. Furthermore, Mr. Pal has experience in in-vitro biological testing, including assays for anticonvulsant, anti-inflammatory, and antioxidant activities, ensuring the biological relevance of his synthesized compounds. His ability to combine experimental techniques with computational modeling equips him to approach drug discovery from both theoretical and practical angles, ensuring well-rounded and impactful research outcomes.

📚 Publications

  • Design, synthesis, and biological evaluation of novel 4-(4-ethoxyphenyl)-6-(substituted-phenyl)pyrimidin-2-amine/thiol/hydroxy derivatives as EGFRWT and EGFRT790M inhibitors targeting NSCLC: In-vitro and in-silico exploration
    • Journal: Journal of Molecular Structure
    • DOI: 10.1016/j.molstruc.2024.141227
    • Date: April 2025
    • Contributors: Rohit Pal; Gurubasavaraja Swamy Purawarga Matada; Ghanshyam Teli; Viney Chawla; Pooja A. Chawla
  • Next-generation cancer therapeutics: PROTACs and the role of heterocyclic warheads in targeting resistance
    • Journal: European Journal of Medicinal Chemistry
    • DOI: 10.1016/j.ejmech.2024.117034
    • Date: January 2025
    • Contributors: Ebna Azizal Omar; Rajesh R.; Pronoy Kanti Das; Rohit Pal; Gurubasavaraja Swamy Purawarga Matada; Lalmohan Maji
  • Benzothiazole a privileged scaffold for cutting-edge anticancer agents: Exploring drug design, structure-activity relationship, and docking studies
    • Journal: European Journal of Medicinal Chemistry
    • DOI: 10.1016/j.ejmech.2024.116831
    • Date: December 2024
    • Contributors: Aayishamma I; Gurubasavaraja Swamy Purawarga Matada; Rohit Pal; Abhishek Ghara; Nimmagadda Venkata Satya Sai Aishwarya; Kumaraswamy B; Ketan R. Hosamani; Manjushree B V; Haripriya E
  • An outlook of docking analysis and structure-activity relationship of pyrimidine-based analogues as EGFR inhibitors against non-small cell lung cancer (NSCLC)
    • Journal: Journal of Biomolecular Structure and Dynamics
    • DOI: 10.1080/07391102.2023.2252082
    • Date: December 11, 2024
    • Contributors: Rohit Pal; Ghanshyam Teli; Sindhuja Sengupta; Lalmohan Maji; Gurubasavaraja Swamy Purawarga Matada
  • Exploring the anticancer potential of triazine derivatives: An outlook of designing strategies, docking studies, and structure-activity relationships (SAR)
    • Journal: ChemistrySelect
    • DOI: 10.1002/slct.202402766
    • Date: November 2024
    • Contributors: B. V. Manjushree; Gurubasavaraja Swamy Purawarga Matada; Rohit Pal; Md. Ashadul Sk; M. P. Viji; Nimmagadda Venkata Satya Sai Aishwarya; Pronoy Kanti Das; I. Aayishamma; S. Mounika
  • Pyrazole, pyrazoline, and fused pyrazole derivatives: New horizons in EGFR-targeted anticancer agents
    • Journal: Chemistry & Biodiversity
    • DOI: 10.1002/cbdv.202400880
    • Date: November 2024
    • Contributors: Ketan R Hosamani; Hemalatha K; Rohit Pal; Gurubasavaraja Swamy Purawarga Matada; Kumaraswamy B; Aayishamma I; Nimmagadda Venkata Satya Sai Aishwarya

Conclusion 

Mr. Rohit Pal is an exceptionally talented and promising researcher in the field of pharmaceutical sciences. His research, focused on Pyrimidine derivatives as EGFR inhibitors for Non-Small Cell Lung Cancer (NSCLC), is not only innovative but holds significant promise for advancing cancer treatment. His combination of chemical synthesis, computational drug design, and biological testing reflects his multidisciplinary approach to pharmaceutical research. Mr. Pal’s commitment to anti-inflammatory, anticonvulsant, and pharmacognostic standardization further demonstrates his versatility as a researcher. While still in the early stages of his career, his publication record and expertise in molecular docking and drug design suggest that he is well on his way to becoming a leader in pharmaceutical research. His ongoing work could contribute to groundbreaking advancements in cancer therapy, neurological disorder treatments, and sustainable drug sourcing. With his strong educational background, solid professional experience, and growing body of work, Mr. Rohit Pal is undoubtedly a candidate with the potential to make meaningful contributions to drug development and global health. His future in research looks bright, and he is well-positioned for recognition in upcoming awards such as the Young Scientist Award.